4/A: Protara Therapeutics Director Richard S. Levy Acquires 20,000 Shares

Director Richard S. Levy purchased 20,000 shares of Protara Therapeutics (TARA) common stock at an average price of $3.19 on May 14, 2025.

Summary

• On May 14, 2025, Richard S. Levy, a director of Protara Therapeutics, Inc. (TARA), purchased 20,000 shares of common stock.
• The shares were acquired at a weighted average price of $3.19, with individual transactions ranging from $3.15 to $3.22.
• Following the transaction, Levy directly owns 51,000 shares of Protara Therapeutics.
• This Form 4/A is an amendment to a previous filing to correct that the transactions were purchases, not sales.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. A director purchasing shares suggests confidence, but the transaction is relatively small and routine.

Positives

• A director's purchase of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Insider transactions are closely monitored by investors as they can provide insights into management's perspective on the company's valuation and future performance. A purchase by a director is generally viewed favorably.

Stakeholder Impact

• The stock purchase could have a minor positive impact on shareholder sentiment.

Key Dates

Keywords

Protara Therapeutics, TARA, Richard S. Levy, stock purchase, Form 4, director, beneficial ownership, amendment